Improved analysis
Prostate cancer is the most common cancer in men in western countries and is on the rise again.
Prostate cancer is the most common cancer in men in western countries and is on the rise again.
An article published in 2008 determined that capillary electrophoresis mass spectrometry urinary proteome analysis was very accurate in detecting prostate cancer. The same research team has now applied this test in clinical practice and its cost-effectiveness.1
The urinary proteome analysis test was performed on 211 outpatients who had been referred to with suspicious prostate-specific antigen or after digital rectal examination. In 184 data about their follow up and the test results were available for analysis. Prostate cancer was detected by biopsy in 49 cases. The test correctly recognized 42 out of 49 cases, which is a sensitivity of 86%. Out of 135 prostate cancer-negative patients, 79 had a negative response in the urinary proteome analysis, a specificity of 59%. Negative and positive predictive values were 92% and 43%, respectively. In addition, the urinary proteome analysis results agreed in 65.7% of the follow-up reference results.
The team also analysed how cost-effective the procedure was and they concluded that their method was more beneficial than the biopsy approach as fewer biopsies were performed and fewer complications arose as a result.This procedure has many benefits for the patient, including its non‑invasive nature, and it was concluded that the test is a helpful addition to prostate cancer diagnostics.
1. W. Schöfer et al, International Journal of Urology, 19(2), 118–125 (2012).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
